CD8A and neoplasm: Due to the s.c.-vaccination with Ad-mAFP-DC, we expect an effective priming of AFP-specific T-cells explaining more effective tumor infiltration with CD4+-, CD8+-T-cells, more release of tumor antigens and more infiltration of DC within the tumors, as shown in Figure 5c (day 5).